



# COPY

Please type plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

### Complete if Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-33

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
		4,789,673		Donatsch et al.	12/6/1988
		4,798,829		King et al.	1/17/1989
		4,845,092		Sanger et al.	7/4/1989
		4,886,808		King	12/12/1989
		4,910,193		Buchheit	3/20/1990
		4,937,247		King	6/26/1990
		4,942,160		Sanger et al.	7/17/1990
		4,975,436		Tyers	12/4/1990
		4,985,424		van Wijngaarden et al.	1/15/1991
		5,034,398		King	7/23/1991
		5,063,231		Sanger et al.	11/5/1991
		5,098,909		Williams	3/24/1992
		5,192,770		Clark et al.	3/9/1993
		5,204,356		Tyers	4/20/1993
		5,272,154		Dixon et al.	12/21/1993
		5,273,972		Jagdmann et al.	12/28/1993
		5,543,426		Dixon et al.	8/6/1996
		5,446,050		Rosen	8/29/1995
		5,561,149		Azria et al.	10/1/1996
		5,641,802		Arcamone et al.	6/24/1997
		5,773,436		Muller et al.	6/30/1998
		5,985,866		Muller et al.	11/16/1999
		6,492,385		Myers et al.	12/10/2002
		6,500,840		Myers et al.	12/31/2002
		6,599,916		Myers et al.	7/29/2003
		6,624,173		Crooks et al.	9/23/2003
		US 2003/0073707		Walker et al.	4/17/2003
		US 2004/0002513		Mazurov et al.	1/1/2004


Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



COPY

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

### Complete If Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-33

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>2</sup>	Number <sup>3</sup>	Kind Code <sup>5</sup> (if known)				
		JP	2002-30084			1/29/2002		
		GB	2 125 398			3/7/1984		
		EP	0 200 444			11/5/1986		
		EP	0 498 466			8/12/1992		
		EP	1 235 826			9/4/2002		
		WO	92/12149			7/23/1992		
		WO	02/085901			10/31/2002		
		WO	02/100833			12/19/2002		
		WO	02/100858			12/19/2002		
		WO	02/17358			2/28/2002		
		WO	03/022856			3/20/2003		
		WO	03/042210			5/22/2003		
		WO	03/072578			9/4/2003		
		WO	03/078431			9/25/2003		
		WO	03/094830			11/20/2003		
		WO	03/101987			11/12/2003		
		GB	2 145 416			3/27/1985		
		FR	2 548 666			1/11/1985		
		EP	0 214 772			3/18/1987		
		EP	1 079 828			3/7/2001		
		WO	84/00166			1/19/1984		
		WO	85/01048			3/14/1985		

Examiner  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

# COPY

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **3**

### Complete if Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-33

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		S.M. Evans et al., "Probing the 5-HT <sub>3</sub> Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives", Med. Chem. Res. (1993), 3:386-406	
		D. Flammia, "Lobeline: Structure-Affinity Investigation of Nicotinic Acetylcholinergic Receptor Binding", J. Med. Chem. (1999), 42:3726-2731	
		R. Azuma et al., "Metabolism and Disposition of GTS-21, A Novel Drug for Alzheimer's Disease", Xenobiotica (1999), Vol. 29, No. 7, pgs. 747-762	
		K. E. Stevens. Et al., "Selective $\alpha_7$ -nicotinic agonists normalize inhibition of auditory response in DBA mice", Psychopharmacology (1998), 136:320-327	
		R. Azuma et al., "The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat", Elsevier Science Ireland Ltd., Toxicology Letters 110 (1999) pgs. 137-144	
		M. Decker, et al., "Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics", pgs. 1-14	
		M. W. Holladay et al., "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery", Journal of Medicinal Chemistry, Vol. 40, No. 26, (1997), pgs. 4169-4194.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

# COPY

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/669,645</td> </tr> <tr> <td>Filing Date</td> <td>September 25, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Ashok Tehim</td> </tr> <tr> <td>Group Art Unit</td> <td>1644 / 1625</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned <i>C. J. Tehim</i></td> </tr> <tr> <td>Attorney Docket Number</td> <td>MEMORY-33</td> </tr> </table>		Application Number	10/669,645	Filing Date	September 25, 2003	First Named Inventor	Ashok Tehim	Group Art Unit	1644 / 1625	Examiner Name	Unassigned <i>C. J. Tehim</i>	Attorney Docket Number	MEMORY-33
Application Number	10/669,645														
Filing Date	September 25, 2003														
First Named Inventor	Ashok Tehim														
Group Art Unit	1644 / 1625														
Examiner Name	Unassigned <i>C. J. Tehim</i>														
Attorney Docket Number	MEMORY-33														
Sheet	1	of	2												

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
k		S.M. Evans et al., "Probing the 5-HT <sub>3</sub> Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives", Med. Chem. Res. (1993), 3:386-406	
k		D. Flammia, "Lobeline: Structure-Affinity Investigation of Nicotinic Acetylcholinergic Receptor Binding", J. Med. Chem. (1999), 42:3726-2731	
k		R. Azuma et al. "Metabolism and Disposition of GTS-21, A Novel Drug for Alzheimer's Disease", Xenobiotica (1999), Vol. 29, No. 7, pgs. 747-762	
k		K. E. Stevens. Et al., "Selective $\alpha$ -7-nicotinic agonists normalize inhibition of auditory response in DBA mice", Psychopharmacology (1998), 136:320-327	
k		R. Azuma et al., "The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat", Elsevier Science Ireland Ltd., Toxicology Letters 110 (1999) pgs. 137-144	
k		M. Decker, et al., "Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics", pgs. 1-14 (2000)	
k		M. W. Holladay et al., "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery", Journal of Medicinal Chemistry, Vol. 40, No. 26, (1997), pgs. 4169-4194.	

Examiner Signature	<i>Raymond Conington</i>	Date Considered	11/8/06
--------------------	--------------------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



COPY

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1014 1625
Examiner Name	Unassigned Gaurang/ta
Attorney Docket Number	MEMORY-33

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
JP		JP	2002-30084			1/29/2002		
GB		GB	2 125 398			3/7/1984		
EP		EP	0 200 444			11/5/1986		
EP		EP	0 498 466			8/12/1992		
EP		EP	1 235 826			9/4/2002		
WO		WO	92/12149			7/23/1992		
WO		WO	02/085901			10/31/2002		
WO		WO	02/100833			12/19/2002		
WO		WO	02/100858			12/19/2002		
WO		WO	02/17358			2/28/2002		
WO		WO	03/022856			3/20/2003		
WO		WO	03/042210			5/22/2003		
WO		WO	03/072578			9/4/2003		
WO		WO	03/078431			9/25/2003		
WO		WO	03/094830			11/20/2003		
WO		WO	03/101987			11/12/2003		
GB		GB	2 145 416			3/27/1985		
FR		FR	2 548 666			1/11/1985		
EP		EP	0 214 772			3/18/1987		
EP		EP	1 079 828			3/7/2001		
WO		WO	84/00166			1/19/1984		
WO		WO	85/01048			3/14/1985		

Examiner Signature	<i>Raymond Gaurang</i>	Date Considered	11/8/06
--------------------	------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.